Memory Disorders Clinical Trial
— GWI HDtDCSOfficial title:
Treatment of Memory Disorders in Gulf War Illness With High Definition Transcranial Direct Cortical Stimulation
A debilitating and common symptom in Gulf War Illnesses (GWI) is the inability to retrieve words. This affects one's conversations, ability to fluidly exchange information verbally and retrieve information from memory. The investigators have discovered 3 brain regions - the PreSupplementary Motor Area (preSMA), caudate nucleus, and the thalamus - that are essential for word retrieval. They have also detected abnormal EEG signals related to these regions in GWI patients who have problems retrieving words. The investigators have used their model of verbal retrieval to design a noninvasive, nonpharmacological treatment that uses High Definition transcranial Direct Current Stimulation (HD tDCS). Using HD tDCS, they deliver small amounts of electric current to areas of the head to stimulate specific brain regions. The objective is to determine if delivery of HD tDCS over the preSMA will improve performance in GWI veterans with a verbal retrieval deficit. The investigators will administer pre-treatment tests of verbal retrieval measures while recording brain electrical activity. They will then administer 10 sessions of HD tDCS over the preSMA (20 minutes a session) in half the veterans. The other half will go through the same procedures, except the current will not be turned on (called the sham condition). The investigators will then compare performance between the "active" and sham group and assess if the treatment had a significant effect on performing verbal retrieval tasks and if there is a change in the ERP markers to account for how the treatment worked. If the treatment is found to be effective it will be offered to those in the sham group at the study's end. The investigators predict this treatment regimen will lead to positive effects on a person's daily functions, especially improved conversational abilities, with few, if any, side effects. They hope to outline the standard procedures for physicians to perform the treatment by creating a manual on how to apply the treatment in a clinical setting so that it will be quickly available to use in multiple sites if the proposed study demonstrates that it is efficacious. This treatment can be made widely available for Warrior Transition Units, military clinics, and VA medical centers. In addition, if successful, this could potentially lead to development of other targets of stimulation to improve other cognitive deficits in GWI, and help alleviate verbal fluency deficits associated with other disorders.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 29, 2024 |
Est. primary completion date | September 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 78 Years |
Eligibility | Inclusion Criteria: - US military veterans serving during the 1990-1991 GW and were deployed to the theater of operations in Southwest Asia (i.e., Iraq, Kuwait, and Saudi Arabia) who are capable of understanding and signing an informed consent document. - between the ages of 18 and 50 years old DURING SERVICE in the Gulf War (born between 1940 and 1973). - Any gender, race/ethnicity, and both enlisted and officer ranks will be included. - English speakers because not all of the screening forms, questionnaires, and tests are available in languages other than English. - right-handed Exclusion Criteria: - non-English speakers because not all of the screening forms, questionnaires, and tests are available in any language except English. - a history of a neurological disorder, including dementia of any type, moderate to severe traumatic brain injury (TBI), brain tumors, present or past drug abuse, stroke, blood vessel abnormalities in the brain, Parkinson's disease, Huntington's disease, or multiple sclerosis. Traumatic brain injury will be screened by history. - anyone cognitively or clinically incompetent to give informed consent. - taking medications that interact with the tDCS effect including amphetamines, L-dopa, carbamazepine, sulpiride, pergolide, lorazepam, rivastigmine, dextromethorphan, D-cycloserine, flunarizine, ropinirole,or citalopram. - cardiac pacemakers, implanted medication pumps of any sort, or a history of bad heart disease, and/or the presence of any metal objects in or near the head which cannot be safely removed for the duration of this study which could be affected by tDCS or affect the administration of tDCS. |
Country | Name | City | State |
---|---|---|---|
United States | Callier Center for Communication Disorders at The University of Texas at Dallas | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas at Dallas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in performance on the Controlled Oral Word Association Test (COWAT) | The COWAT is a verbal fluency test that measures spontaneous production of words belonging to the same category or beginning with some designated letter. | Phone screen, beginning of HD tDCS/sham treatment, after HDtDCS/sham (2 weeks), at 3 month follow-up and 6 month follow-up. | |
Primary | Change in the performance on the California Verbal Learning Test (CVLT) | The CVLT is a measure of episodic verbal learning and memory. The test does this by attempting to link memory deficits with impaired performance on specific tasks. It assesses encoding, recall and recognition in a single modality of item presentation (auditory-verbal). | Beginning of HD tDCS/sham treatment, after HDtDCS/sham (2 weeks), at 3 month follow-up and 6 month follow-up | |
Secondary | Change in the performance on the Semantic Object Retrieval Test (SORT) | The SORT was developed for the assessment of semantic memory and subsequent name production, and has been shown to detect word retrieval deficits in other neurological diseases. | Beginning of HD tDCS/sham treatment, after HDtDCS/sham (2 weeks), at 3 month follow-up and 6 month follow-up | |
Secondary | Change in the performance on the Semantic Selection Task | This is a go/no-go task performed during EEG. | Beginning of HD tDCS/sham treatment, after HDtDCS/sham (2 weeks), at 3 month follow-up and 6 month follow-up | |
Secondary | Change in the performance on the Event Related Potential (ERP) | ERP is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. This provides a noninvasive means of evaluating brain functioning. ERPs are measured by electroencephalography (EEG). | Beginning of HD tDCS/sham treatment, after HDtDCS/sham (2 weeks), at 3 month follow-up and 6 month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03894254 -
Predictive Factors of Autonomy Loss in Real-life Cohort
|
N/A | |
Not yet recruiting |
NCT03507985 -
Attention and Memory Disorders Related to Acute Morphine
|
||
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT00355498 -
Amyloid Plaque and Tangle Imaging in Aging and Dementia
|
||
Completed |
NCT00010920 -
Preventing Cognitive Decline With Alternative Therapies
|
Phase 3 | |
Not yet recruiting |
NCT04079075 -
Multiple Interventions to Prevent Cognitive Decline
|
N/A | |
Completed |
NCT02185222 -
Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint
|
Phase 3 | |
Completed |
NCT00289471 -
Identifying Patients With Dementia in Primary Care
|
N/A | |
Terminated |
NCT00548327 -
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
|
Phase 2 | |
Completed |
NCT00387062 -
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment
|
Phase 1 | |
Completed |
NCT00403507 -
Exercise Treatment of Mild-Stage Probable Alzheimer's Disease
|
Phase 2 | |
Completed |
NCT04587583 -
WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers
|
Phase 1/Phase 2 | |
Completed |
NCT02843529 -
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
|
N/A | |
Active, not recruiting |
NCT03205709 -
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05509075 -
Nutraceuticals and Functional Foods
|
||
Recruiting |
NCT05065450 -
Amygdala Memory Enhancement
|
N/A | |
Recruiting |
NCT05929144 -
Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases
|
N/A | |
Active, not recruiting |
NCT03661034 -
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
|
N/A | |
Completed |
NCT02333942 -
Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
|
||
Completed |
NCT02236416 -
Physical Exercise for Prevention of Dementia
|
N/A |